DK1778618T3 - Synthesis of triethylenetetramines - Google Patents

Synthesis of triethylenetetramines

Info

Publication number
DK1778618T3
DK1778618T3 DK05805036.0T DK05805036T DK1778618T3 DK 1778618 T3 DK1778618 T3 DK 1778618T3 DK 05805036 T DK05805036 T DK 05805036T DK 1778618 T3 DK1778618 T3 DK 1778618T3
Authority
DK
Denmark
Prior art keywords
triethylenetetramines
synthesis
Prior art date
Application number
DK05805036.0T
Other languages
Danish (da)
Inventor
Marco Jonas
Irene Vaulont
Antonio Soi
Gunther Schmidt
Original Assignee
Philera New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36036723&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1778618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Philera New Zealand Ltd filed Critical Philera New Zealand Ltd
Application granted granted Critical
Publication of DK1778618T3 publication Critical patent/DK1778618T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
    • C07C209/48—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/76—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by nitration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/13—Amines containing three or more amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/30—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK05805036.0T 2004-07-19 2005-07-19 Synthesis of triethylenetetramines DK1778618T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58908004P 2004-07-19 2004-07-19
PCT/IB2005/052421 WO2006027705A2 (en) 2004-07-19 2005-07-19 Synthesis of triethylenetetramines

Publications (1)

Publication Number Publication Date
DK1778618T3 true DK1778618T3 (en) 2014-03-10

Family

ID=36036723

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05805036.0T DK1778618T3 (en) 2004-07-19 2005-07-19 Synthesis of triethylenetetramines

Country Status (8)

Country Link
US (8) US7582796B2 (en)
EP (1) EP1778618B1 (en)
AU (1) AU2005281353A1 (en)
CA (3) CA2875095C (en)
DK (1) DK1778618T3 (en)
ES (1) ES2449066T3 (en)
PT (1) PT1778618E (en)
WO (1) WO2006027705A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2478997C (en) 2002-03-08 2013-12-17 Protemix Corporation Limited Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
JP2006503014A (en) 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド Dosage forms and related treatments
CA2875095C (en) 2004-07-19 2019-09-03 Philera New Zealand Limited Synthesis of triethylenetetramines
CA3018698A1 (en) * 2005-11-09 2007-05-18 Philera New Zealand Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
WO2008104579A1 (en) * 2007-03-01 2008-09-04 Basf Se Method for producing ethylenediamine diacetonitrile
CN101675025B (en) * 2007-03-01 2015-04-08 巴斯夫欧洲公司 Method for producing tetraethylenepentamine
KR20090122435A (en) 2007-03-01 2009-11-30 바스프 에스이 Novel method for producing teta by means of eddn
US7960591B2 (en) * 2007-03-01 2011-06-14 Basf Se Method for producing triethylenetetramine
US7880036B2 (en) * 2007-03-01 2011-02-01 Basf Se Production method for ethyleneamine mixtures
EP2350212A4 (en) * 2008-11-07 2012-05-23 Huntsman Petrochemical Llc Polyaminoacetonitriles, their methods of preparation and use
WO2010146009A1 (en) 2009-06-18 2010-12-23 Basf Se Methyl-substituted teta compounds
US8309179B2 (en) * 2009-09-28 2012-11-13 Rohm And Haas Electronics Materials Llc Selenium/group 1b ink and methods of making and using same
KR20130037667A (en) 2010-03-02 2013-04-16 바스프 에스이 The use of linear triethylentetramine as curing agent for epoxy resins
DE102011083324A1 (en) * 2011-09-23 2013-03-28 Henkel Ag & Co. Kgaa Oral and dental care and cleaning products with polyamines
CN102924289B (en) * 2012-11-07 2014-11-12 广东奥尔诚药业有限公司 Synthetic process of hydrochloric acid trientine
WO2014131674A2 (en) 2013-03-01 2014-09-04 Basf Se Amine composition
US20160084057A1 (en) * 2014-09-24 2016-03-24 Baker Hughes Incorporated Concentric coil tubing deployment for hydraulic fracture application
CN104387336B (en) * 2014-10-24 2016-04-27 上海应用技术学院 Isosorbide-5-Nitrae, the preparation method of 7,10-tetraazacyclododecanand and nanofiltration membrane thereof
CN106278907B (en) * 2014-12-17 2019-06-21 四川科瑞德凯华制药有限公司 A kind of Syprine Hydrochloride compound
JP6889116B2 (en) 2015-02-03 2021-06-18 カドモン ファーマシューティカルズ，リミティド ライアビリティ カンパニー Stable trientine preparation
EP3350154B1 (en) * 2015-09-18 2021-02-17 Emcure Pharmaceuticals Limited An improved process for preparation of trientine dihydrochloride
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
WO2017213524A1 (en) * 2016-06-10 2017-12-14 Garth Cooper Treatment of neurodegenerative disorders
CN108203423A (en) * 2016-12-20 2018-06-26 中国医学科学院药物研究所 Cumarin Mannich base and its purposes in neurodegenerative disease is prevented
WO2018193482A1 (en) * 2017-04-22 2018-10-25 Biophore India Pharmaceuticals Pvt. Ltd. Improved method for the synthesis of 1,2-ethanediamine, n, n'-bis(2-aminoethyl)-dihydrochloride(trientine dihydrochloride)
WO2019073427A1 (en) * 2017-10-12 2019-04-18 Piramal Enterprises Limited A process for the preparation of trientine dihydrochloride
WO2019106123A1 (en) * 2017-12-01 2019-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of triethylenetetramine (teta) for the therapeutic induction of autophagy
CA3096423A1 (en) 2018-05-04 2019-11-07 Gmp-Orphan Sa Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
CN109459518A (en) * 2018-12-26 2019-03-12 环境保护部南京环境科学研究所 The extraction and detection method of lipid in organism liver organization
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
EP3982943A4 (en) * 2019-06-17 2023-07-05 Philera New Zealand Ltd. Combination treatments for central nervous system disorders
KR102489293B1 (en) * 2020-10-15 2023-01-17 (주) 에프엔지리서치 High purification of technical grade triethylenetetramine
CN117157064A (en) * 2021-03-05 2023-12-01 菲勒拉新西兰有限责任公司 Treatment of copper disorders
TWI819502B (en) 2022-02-23 2023-10-21 裕捷股份有限公司 Triethylenetetramine tetrahydrochloride and its preparation method and composition
CN116675607A (en) * 2022-02-23 2023-09-01 裕捷股份有限公司 Triethylenetetramine tetrahydrochloride and preparation method and composition thereof
US20230364031A1 (en) * 2022-04-19 2023-11-16 Garth Cooper Treatment of brain copper disorders
WO2024018394A1 (en) * 2022-07-19 2024-01-25 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of crystalline form a of n, n'-bis(2-aminoethyl)-1,2-ethanediamine tetrahydrochloride
US20240043370A1 (en) * 2022-08-07 2024-02-08 Philera New Zealand Ltd. Method for triethylenetetramine purification

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US159364A (en) * 1875-02-02 Improvement in cisterns
US9534A (en) * 1853-01-11 haydbn
US159489A (en) * 1875-02-02 Improvement in flat-iron heaters
US3791988A (en) 1972-03-23 1974-02-12 Hoffmann La Roche Diagnostic test for glucose
PL105793B1 (en) * 1977-11-24 1979-10-31 METHOD OF OBTAINING SALTS OF DICARBOXYLIC ACIDS AND POLYAMINE
CS197093B1 (en) * 1978-06-16 1980-04-30 Ivo Kuhr Process for preparing pure dihydtochloride of triethylentetramine
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4323558A (en) 1979-09-10 1982-04-06 Nelson Research & Development Co. Topical trien containing pharmaceutical compositions and methods of use
US4371374A (en) 1980-11-17 1983-02-01 The Rockefeller University Monitoring metabolic control in diabetic patients by measuring glycosylated amino acids and peptides in urine
JPS57144215A (en) 1981-03-02 1982-09-06 Nippon Nousan Kogyo Kk Composition for improving lipometabolism
DE3217071A1 (en) 1982-05-06 1983-11-10 Rüdiger Dr. 6365 Rosbach Gröning Pharmaceutical composition for oral administration with improved bioavailability of the active substances
US4758583A (en) 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5852009A (en) 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US4665192A (en) 1984-03-19 1987-05-12 The Rockefeller University 2-(2-furoyl)-4(5)-2(furanyl)-1H-imidazole
US4578583A (en) 1984-04-03 1986-03-25 The Babcock & Wilcox Company Solid state ultraviolet flame detector
JPH01500589A (en) 1986-03-21 1989-03-01 ユーラシアム　ラボラトリーズ　インコーポレーテツド pharmaceutical composition
CH667590A5 (en) 1986-07-24 1988-10-31 Inpharzam Int Sa WATER-SOLUBLE EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN. .
CH666814A5 (en) 1986-07-24 1988-08-31 Inpharzam Int Sa WATER-SOLUBLE PHARMACEUTICAL COMPOSITION CONTAINING N-ACETYL-CISTEIN.
US4866090A (en) 1988-01-07 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
EP0331014A3 (en) 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Use of ace inhibitors in diabetes prophylaxis
JPH01294631A (en) 1988-05-19 1989-11-28 Sanwa Kagaku Kenkyusho Co Ltd Remedy and preventive for diabetic disease, food and drink and table luxury
US5077313A (en) 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
US5447728A (en) 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
ES2106318T3 (en) 1991-12-06 1997-11-01 North Shore Univ Hospital METHOD TO REDUCE INFECTIONS RELATED TO MEDICAL DEVICES.
US5246970A (en) 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
JP3157622B2 (en) 1992-06-05 2001-04-16 株式会社ミツカングループ本社 Fructosylamine deglycase, method for producing the same, and method for quantifying amadori compound using the enzyme
JPH07118148A (en) 1993-10-26 1995-05-09 Tsumura & Co Preventive for hepatoma
US5420120A (en) 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
WO1995017900A1 (en) 1993-12-30 1995-07-06 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
US5854271A (en) 1994-05-02 1998-12-29 Cytos Pharmaceuticals, L.L.C. Effective method for the amelioration and prevention of tissue and cellular damage
WO1996012483A1 (en) 1994-10-25 1996-05-02 Washington University Method of inhibiting nitric oxide formation
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
US5906996A (en) 1996-08-21 1999-05-25 Murphy; Michael A. Tetramine treatment of neurological disorders
EP1007048A4 (en) 1997-03-11 2004-09-22 Gen Hospital Corp Identification of agents for use in the treatment of alzheimer's disease
US5811446A (en) 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US20050085555A1 (en) 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US20030013772A1 (en) 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US6576672B1 (en) 1998-08-21 2003-06-10 Michael A. Murphy Polyamine treatment of neurological disorders
US5980914A (en) 1997-08-22 1999-11-09 P.N. Gerolymatos S.A. Clioquinol for the treatment of Parkinson's disease
US6821954B2 (en) 1997-09-18 2004-11-23 Auckland Uniservices Limited Compounds and uses thereof in treating bone disorders
US5972985A (en) 1997-11-03 1999-10-26 Cytos Pharmaceuticals, Llc Histidine containing nutriceutical compositions
AU754681B2 (en) 1998-02-04 2002-11-21 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
US6323218B1 (en) 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6147070A (en) 1998-06-05 2000-11-14 Facchini; Francesco Methods and compositions for controlling iron stores to treat and cure disease states
EP1234585A3 (en) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
AU772616B2 (en) 1998-09-25 2004-05-06 Protemix Corporation Limited Fructosamine oxidase assay: methods and materials
JP2000204037A (en) 1999-01-12 2000-07-25 Tsumura & Co Therapeutic agent for amyotrophic lateral sclerosis
US6309380B1 (en) 1999-01-27 2001-10-30 Marian L. Larson Drug delivery via conformal film
US20030166561A1 (en) 1999-06-18 2003-09-04 Cooper Garth J. S. Peptide
CN1296384C (en) 1999-06-18 2007-01-24 普罗特米克斯发现有限公司 Peptide having preptin functionality
US20030050434A1 (en) 1999-06-18 2003-03-13 Cooper Garth J.S. Peptide
DE60129427T3 (en) 2000-05-11 2014-07-24 The Procter & Gamble Company HIGHLY CONCENTRATED LAUNDRY SPRAY COMPOSITIONS AND COMPOUNDS CONTAINING THEM
FR2810035B1 (en) * 2000-06-13 2004-04-16 Air Liquide PROCESS FOR THE PREPARATION OF TETRAAZA MACROCYCLES AND NEW COMPOUNDS
EP1370254B1 (en) 2000-12-01 2008-01-16 Radical Vision Therapeutics Inc. Copper chelators for treating ocular inflammation
US7754765B2 (en) 2000-12-01 2010-07-13 Radical Vision Therapeutics Inc Copper chelators for treating ocular inflammation
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
NZ528509A (en) 2001-03-30 2005-09-30 Protemix Discovery Ltd Phosphoprotein target for insulin and its antagonists
AU2002354951A1 (en) 2001-07-19 2003-03-03 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
CA2471833A1 (en) 2001-11-26 2003-06-05 Protemix Corporation Limited Methods of compositions for normalizing lipid levels in mammalian tissues
US20040038861A1 (en) 2001-11-26 2004-02-26 Cooper Garth J. S. Methods and compositions for normalizing lipid levels in mammalian tissues
AU2003207441A1 (en) 2002-01-03 2003-07-24 Duke University Methods of modulating localization and physiological function of ip3 receptors
CN1886423A (en) 2002-01-18 2006-12-27 普罗特米克斯公司 Glycoisoforms of adiponectin and uses thereof
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
CA2473102A1 (en) 2002-01-29 2003-07-29 Protemix Corporation Limited Suppression of cytotoxic protein conformers
US20050074756A1 (en) 2002-03-01 2005-04-07 Cooper Garth James Smith FALP proteins
AU2003222513A1 (en) 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
CA2478997C (en) 2002-03-08 2013-12-17 Protemix Corporation Limited Use of copper chelating tetraamines for the treatment of cardiovascular disease and heart failure
WO2003082259A1 (en) 2002-04-03 2003-10-09 Puleva Biotech, S.A. Natural phenolic products and derivatives thereof for protection against neurodegenerative diseases
AU2003222533A1 (en) 2002-04-29 2003-11-17 Protemix Corporation Limited Proteins with deglycating activities and methods of using same
WO2003099223A2 (en) 2002-05-24 2003-12-04 The Regents Of The University Of Michigan Copper lowering treatment of inflammatory and fibrotic diseases
EP1539131A4 (en) 2002-07-23 2009-07-08 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US7189865B2 (en) 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
US20060116318A1 (en) 2002-08-01 2006-06-01 Jillian Cornish Preptin methods of use
US20040142393A1 (en) 2002-08-01 2004-07-22 Cooper Garth James Smith Methods of use of compounds with preptin function
CA2494308A1 (en) 2002-08-01 2004-02-12 Protemix Corporation Limited Methods of use of compounds with preptin function
JP2006503014A (en) 2002-08-20 2006-01-26 プロテミックス コーポレイション リミティド Dosage forms and related treatments
WO2004017957A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
WO2004056861A2 (en) 2002-12-23 2004-07-08 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070185072A1 (en) 2003-03-21 2007-08-09 Christophe Boldron Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
WO2004087160A1 (en) 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
WO2004100884A2 (en) 2003-05-07 2004-11-25 Dmi Biosciences, Inc. Oral care methods and products
US7176239B2 (en) 2003-07-11 2007-02-13 Suming Wang Methods and compositions for treatment of Ataxia-telangeictasia
WO2005040205A1 (en) 2003-10-28 2005-05-06 Protemix Discovery Limited Peptides with anti-obesity activity and other related uses
DE20316977U1 (en) 2003-11-03 2005-03-17 Neoperl Gmbh backflow preventer
CA2550505A1 (en) 2003-12-19 2005-06-30 Protemix Corporation Limited Copper antagonist compounds
CA2875095C (en) 2004-07-19 2019-09-03 Philera New Zealand Limited Synthesis of triethylenetetramines
WO2006068516A1 (en) 2004-12-20 2006-06-29 Protemix Corporation Limited Implantable medical devices coated with or containing copper chelating compounds

Also Published As

Publication number Publication date
US11795150B2 (en) 2023-10-24
US20130345311A1 (en) 2013-12-26
PT1778618E (en) 2014-03-04
WO2006027705A3 (en) 2006-07-13
EP1778618B1 (en) 2013-12-25
EP1778618A4 (en) 2008-07-16
US9556123B2 (en) 2017-01-31
AU2005281353A1 (en) 2006-03-16
CA2875095C (en) 2019-09-03
US8912362B2 (en) 2014-12-16
US8394992B2 (en) 2013-03-12
US20170226064A1 (en) 2017-08-10
US20150057466A1 (en) 2015-02-26
CA2577634C (en) 2015-07-07
CA2577634A1 (en) 2006-03-16
CA2875095A1 (en) 2006-03-16
EP1778618A2 (en) 2007-05-02
US20160102060A1 (en) 2016-04-14
US20100173994A1 (en) 2010-07-08
ES2449066T3 (en) 2014-03-18
US20060041170A1 (en) 2006-02-23
US20120029203A1 (en) 2012-02-02
CA3050047A1 (en) 2006-03-16
US8067641B2 (en) 2011-11-29
US20200148647A1 (en) 2020-05-14
US7582796B2 (en) 2009-09-01
WO2006027705A2 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
DK1778618T3 (en) Synthesis of triethylenetetramines
DK2377869T3 (en) Synthesis of Bortezomib
DK1802579T3 (en) Derivatives of 3-arylaminopyridine
DK1992697T3 (en) Preparation of TNFR-Fc
DK1720866T3 (en) Course of action
DK1931315T3 (en) Depot formulations of nalbufin
DK1658295T3 (en) Regioselective synthesis of CCI-779
ATE414693T1 (en) NOVEL CIS-IMIDAZOLINES
DK1937071T3 (en) Crystalline modifications of pyraclostrobin
DK1940465T3 (en) New use of anti-IL-1beta antibodies
DK2371818T3 (en) Hydroxybenzoate salts of methanicotine compounds
DK1879844T3 (en) Preparation of sodium deformate
DK1587542T3 (en) Use of anti-CD100 antibodies
NO20055643D0 (en) Preparation of lodixanol
DK1763520T3 (en) Use of trisubstituted benzopyranones
DK2081675T3 (en) Synthesis of biodiesel
DE502005005664D1 (en) Chronograph
DK1516540T3 (en) Use of vitamin D compounds
NO20043305D0 (en) Preparation of lodixanol
DK1730109T3 (en) Synthesis of pyrrole-2-carbonitriles
FR2877833B1 (en) CORRECTEUR OF LORDOSES
DK2301576T3 (en) Therapeutic use of anti-CS1 antibodies
DK1787450T3 (en) Selection of information
SE0402103D0 (en) Novel compounds
ITVR20040028A1 (en) STRUCTURE OF LONGHERONE